LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the start of a limited commercial release for the Essenz™ Perfusion System*. The release has been initiated in select centers throughout Europe, following a successful clinical experience in two major centers, Catharina Hospital in Eindhoven, Netherlands and San Donato Hospital in Milan, Italy. Consisting of a next-generation heart-lung machine (HLM) and a transformative patient monitor, Essenz puts data at the forefront to deliver a patient-tailored approach that supports data-driven decisions during life-saving cardiopulmonary bypass (CPB) procedures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005127/en/
LivaNova's Essenz™ Perfusion System (Photo: Business Wire)
Catharina Hospital was the first hospital in the world to carry out clinical cases with the Essenz Perfusion System. “We are proud to be the first to have introduced the Essenz Perfusion System to our clinical practice, particularly given the great involvement we had with the system throughout the development process,” said Eddy Overdevest, Perfusionist at Catharina Hospital. “From the first day in the operating room, we felt a level of confidence that has allowed us to immediately move into a variety of clinical cases, trusting the system and our own ability to work with it. With the Essenz Perfusion System, we’re entering a new era where technology and the expertise of the perfusionist can seamlessly come together to provide personalized care for our patients.”
“We are very satisfied with the way the machine is performing and excited to finally be able to use it to support patients during open-heart procedures,” said Mauro Cotza, Chief Perfusionist at San Donato Hospital. “We were pleased to be the first hospital in the world to place a patient on bypass with Essenz during a minimally invasive mitral valve replacement surgery.”
The Essenz Perfusion System is based on 50 years of trusted partnership with perfusionists. LivaNova worked hand in hand with more than 300 perfusionists around the world who participated during every step of design and development to address their evolving needs in the operating room (OR), with an emphasis on patient safety and risk management. The comprehensive system provides flexibility and scalability to optimize intra-operative care coordination.
The Essenz Perfusion System is built on the legacy LivaNova S5™ HLM. The Essenz HLM cockpit and Essenz Patient Monitor are connected but operate separately. Plus, each pump on Essenz is controlled individually.
Accurate sensing technology and an intuitive dashboard on the Essenz Patient Monitor provide data during a case. With an intuitive user interface, the Essenz Patient Monitor continuously records and displays data and events together to assist the perfusionist throughout a procedure.
The Essenz Perfusion System features an ergonomic design, including advanced cable management and a mast-mounted design to keep the area clean and hygienic. The innovative cockpit provides one central view to control the device and check all perfusion and patient parameters. Mast-mounted pumps allow the user to position the disposables at their discretion (i.e., oxygenator and perfusion tubing set).
Further, the Essenz Perfusion System is backed by a responsive service team of dedicated, local engineers in more than 100 countries, along with a global support center to address any needs.
“During open-heart procedures, perfusionists play a critical role and the perfusion system they use acts as the patient’s heart and lungs during the operation,” said Marco Dolci, President, Cardiopulmonary at LivaNova. “Throughout the Essenz design process, we heard directly from perfusionists that they need a flexible and reliable system that gives them access to comprehensive data to inform their patient-tailored support in the OR. With the combination of next-generation hardware and software, the Essenz Perfusion System will serve patients and empower perfusionists to make informed decisions as they provide increasingly tailored patient care.”
Both the Essenz HLM and Essenz Patient Monitor have received CE Mark and are currently pending regulatory approval in other key geographies. Learn more about the Essenz Perfusion System and Essenz Patient Monitor on the LivaNova website.
*Note: The Essenz Heart-Lung Machine is not available for sale in all geographies. Visit the LivaNova website for important safety information. Not available in Canada or the U.S. 510(k) clearance pending.
About LivaNova
LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.
Safe Harbor Statement
This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Essenz Perfusion System, Essenz HLM and the Essenz Patient Monitor. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005127/en/
Contact information
LivaNova Investor Relations and Media Contacts
+1 281-895-2382
Briana Gotlin
Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 18:59:00 EET | Press release
Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through battle-tested AI Agents at enterprise scale. The new funds will accelerate the adoption of the Torq AI SOC Platform, the only end-to-end solution built on
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom